Scope of report
- The report provides a snapshot of the global therapeutic landscape of Amyotrophic lateral sclerosis.
- The report assesses Amyotrophic lateral sclerosis pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Amyotrophic lateral sclerosis pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Amyotrophic lateral sclerosis ranging from discovery to pre-registration and undisclosed stages.
Sanofi-Synthelabo, Sanofi-aventis, Fidia Farmaceutici; Roche Palo Alto LLC, Toyama Chemical, Mitsubishi Pharma Corporation, Pharmacyclics, Cephalon, Regeneron Pharmaceuticals, Santen Pharmaceutical, Ono Pharmaceutical, Purdue Pharma, Vasogen, SYGNIS Bioscience GmbH, Phytopharm, Rinat Neuroscience, ViaCell, Faust Pharmaceuticals, Eisai Co Ltd, Isis Pharmaceuticals, NeuroNova AB, Sangamo BioSciences, Psyadon Pharmaceuticals, Sirtris Pharmaceuticals, CepTor Corporation, Metabolic Pharmaceuticals, Neuren Pharmaceuticals, Celgene Corporation, Cambria Biosciences LLC, Metabolon, GEMACBIO, Saneron CCEL Therapeutics, Reata Pharmaceuticals, Trophos, Avicena Group, Addex Pharmaceuticals, Neurosciences Victoria, Neurotune, ReceptoPharm, Neuralstem, KineMed, Anavex Life Sciences, Genzyme Corporation
Eliprodil, Xaliproden, T 588, Oxothiazolidine carboxylate, Edaravone, Riluzole, Motexafin gadolinium, Neurturin, Mecasermin, Dapiclermin, Cutamesine, Talampanel, ARR 17477, ZVAD fmk, WHIP 131, Arundic acid, GPI 5693, PC 01, EN 101
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800